Rosuvastatin
- Generic Name
- Rosuvastatin
- Brand Names
- Crestor, Ezallor, Roszet
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28FN3O6S
- CAS Number
- 287714-41-4
- Unique Ingredient Identifier
- 413KH5ZJ73
- Background
Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...
- Indication
The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...
- Associated Conditions
- Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
- Associated Therapies
- Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Crestor Versus Placebo in Subjects With Heart Failure
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5013
- Registration Number
- NCT00206310
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00184951
- Locations
- 🇳🇱
University of Leiden, Leiden, Netherlands
🇳🇱University of Amsterdam, Amsterdam, Netherlands
🇩🇪University of Bonn, Bonn, Germany
Impact of Rosuvastatin on Endothelial Function and Inflammation in Patients With Chronic Heart Failure
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-08-01
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 40
- Registration Number
- NCT00176332
- Locations
- 🇩🇪
University of Leipzig, Heart Center, Department of Internal Medicine / Cardiology, Leipzig, Saxony, Germany
Rosuvastatin and Renal Endothelial Function
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 46
- Registration Number
- NCT00160745
- Locations
- 🇩🇪
CRC, Medizinische Klinik 4 - Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Krankenhausstrase 12, Germany
Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126)
- Conditions
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2011-12-22
- Target Recruit Count
- 86
- Registration Number
- NCT00117494
- Locations
- 🇫🇷
service de Médecine Interne Hopital Hotel Dieu, Paris, France
Rho Kinase in Patients With Atherosclerosis
- Conditions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2007-04-24
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00115830
- Locations
- 🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
Rosuvastatin Affecting Aortic Valve Endothelium
- Conditions
- First Posted Date
- 2005-06-16
- Last Posted Date
- 2006-10-31
- Lead Sponsor
- Hospital Pedro Hispano
- Target Recruit Count
- 200
- Registration Number
- NCT00114491
- Locations
- 🇵🇹
Hospital Pedro Hispano, Porto, Portugal
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00079638
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.